There is an interesting takeaway from Monday’s session as the index managed to close above the midpoint of the prior trending bar. Usually, after the formation of the big bar, the price stalls around the midpoint of that trading bar. In the current case, the index has managed to close above the midpoint of a big bearish bar, which indicates that the bulls are regrouping.  

Let’s have a sneak peek of the conversation between DSIJ MF team and Mahendra Jajoo, CIO – Fixed Income, Mirae Asset Investment Managers (India) Private Limited.

MTAR Technologies is a precision engineering solutions company. It is coming out with its IPO. Read on to find if you should subscribe to the issue. 

Bulls have made a comeback as the domestic benchmark indices rallied on Monday, starting the last month of the financial year FY21 with a 'boom'. Sensex surged 749.85 points or 1.53 per cent to close at 49,849.84 levels while Nifty jumped 232.40 points or by 1.6 per cent to settle at 14,761.55 levels. 

Rites Limited has bagged major orders worth Rs 93 crore, approximately. The orders include turnkey order of signalling works from Ministry of Railways amounting to Rs 67.18 crore as well as the extension of general consultancy work for Nagpur Metro rail project.

Hinduja Group flagship company, Ashok Leyland gained one per cent intraday on March 01, 2021, after the company reported its monthly sales figure for the month of February 2021.   

Sterlite Technologies Ltd (STL) today announced major new deals and extensions to current engagement with leading telcos in the Middle East and Africa region (MEA). The deals worth more than Rs 730 crore take the company's order book to a record high of Rs 11,300 crore.  

Isgec Heavy Engineering announced today that it has received an order for a slop fired boiler from a prestigious company in the sugar industry for their distillery plant.

The company announced the addition of two residential plots in Sanpada (Navi Mumbai) from City & Industrial Development Corporation (CIDCO).

The subsidiary of Biocon Ltd i.e. Biocon Biologics announced on Monday that it has received CHMP approval to market Abevmy, which is a biosimilar to Avastin.